JeffreyCRobinsonMD

Pulmonology • Portland, OR

Critical Care Medicine, Pulmonary Vascular Medicine

Physician in Pulmonary and Critical Care

Join to view full profile

Dr. Robinson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Robinson's full profile

Already have an account?

Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239
Phone+1 503-494-8311

Fax+1 503-346-6854

Summary

Dr. Jeffrey Robinson is a pulmonary and critical care physician in Portland, OR and is associate professor at Oregon Health and Science University. He specializes in pulmonary vascular disease, including pulmonary hypertension and pulmonary embolism management and treatment. He also specializes in critical care medicine and cares for patients in the medical and cardiac intensive care units.

Education & Training

University of ColoradoFellowship, Pulmonary Disease and Critical Care Medicine, 2012 - 2016
University of California Davis HealthChief Residency, Internal Medicine, 2011 - 2012
University of California Davis HealthResidency, Internal Medicine, 2008 - 2011
Albert Einstein College of MedicineClass of 2008

Certifications & Licensure

OR State Medical License 2017 - 2025
CO State Medical License 2013 - 2019
CA State Medical License 2010 - 2012
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Clinical Trials

A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12) Start of enrollment: 2021 May 12
Recruiting
Phase 3
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) Start of enrollment: 2021 Jan 25
Completed
Phase 3
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) Start of enrollment: 2020 Nov 12
Completed
Phase 2
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients Start of enrollment: 2018 Aug 30
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension Start of enrollment: 2020 Jul 07
Terminated
Phase 3
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) Start of enrollment: 2022 Mar 18
Recruiting
Phase 3
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Start of enrollment: 2020 Jun 30
Recruiting
Phase 3
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) Start of enrollment: 2023 Dec 28
Recruiting
Phase 3
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) Start of enrollment: 2024 Jun 01
Not yet recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

11 citations
Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry.
Nicholas A. Kolaitis, Roham T. Zamanian, Vinicio A. de Jesus Perez, David B. Badesch, Raymond L. Benza
Annals of the American Thoracic Society. 2021-04-01
11 citations
Obesity in pulmonary arterial hypertension the pulmonary hypertension association registry
Jeff Min, Rui Feng, David B. Badesch, Erika Berman-Rosenzweig, Charles D. Burger
Annals of the American Thoracic Society. 2021-02-01
96 citations
TGF-β activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension.
Rajesh Kumar, Claudia Mickael, Biruk Kassa, Liya Gebreab, Jeffrey C. Robinson
Nature Communications. 2017-05-30

Journal Articles

TGF-Β Activation by Bone Marrow-Derived Thrombospondin-1 Causes Schistosoma- and Hypoxia-Induced Pulmonary Hypertension
William J Janssen, Jeffrey C Robinson, Rubin M Tuder, Kurt R Stenmark, Nature
Alpha-1 antitrypsin and the pathogenesis of emphysema
Robinson JC, Tuder RM, Hunt J, Minerva Pneumologica, 12/2013

Books/Book Chapters

Pulmonary Circulation: Diseases and Their Treatment
Chapter: Endothelin Receptor Antagonists
Robinson JC, Fox DL, Pugliese S, Dempsey JE, Graham BB, Bull T, Badesch DEditors: Rubin LJ.Taylor and Francis PublishersEdition 4th,2016
Pulmonary Hypertension: Basic Science to Clinical Medicine
Chapter: Defining characteristics of pulmonary hypertension
Robinson JC, Kumar R, Tuder RMEditors: Maron B.Springer GroupEdition 1st,2015

Abstracts/Posters

Long Term Health Outcomes of Individuals with High Altitude Pulmonary Hypertension: A 55-year Follow-up Study
Robinson JC, Abbott C, Roach RC, Honigman B, Bull TM, American Thoracic Society International Conference, San Francisco, CA, 5/2016
Exogenous Iron Supplementation in Acute Hypoxic Pulmonary Hypertension Leads to Decreased Hypoxia Inducible Factor Stabilization and Attenuated Right Ventricular Systo...
Robinson JC, Kumar R, Acosta D, Graham BB, Tuder RM, American Thoracic Society International Conference, Denver, CO, 5/2015
Iron Deficiency is Protective in Experimental Pulmonary Hypertension
Robinson JC, Kumar R, Graham BB, Tuder RM, American Thoracic Society International Conference., San Diego, CA, 5/2014
In a Female Mice Model of Pulmonary Hypertension (Hypoxia/Sugen), the Right Ventricle Adapts with Hypertrophy and Proliferation
Robinson JC, Wong A, Wood T, Li N, Lopez JE, Department of Internal Medicine Academic Forum, University of California, Davis
Hypoxia-induced pulmonary remodeling is associated with re-expression of beta-myosin heavy chain in right and left ventricular cardiac myocytes
Robinson JC, Haynam S, Wong A, Ander B, Chiamvimonvat N, Lopez JE., Department of Internal Medicine Academic Forum, University of California, Davis
Norepinephrine blocks cardiac myocyte regeneration by inducing a developmental program of cell cycle arrest
Robinson JC, Long CS, Simpson PC, Chiamvimonvat N, Lopez JE, Department of Internal Medicine Academic Forum, University of California, Davis
Join now to see all

Professional Memberships

American Thoracic Society - ATS
Member
American Heart Association - AHA
Member
Pulmonary Vascular Research Institute
Member